Scientists Engineer Bacteria to Convert PET Plastic Waste into Parkinson's Drug Levodopa

The research team modified Escherichia coli to enable the conversion of plastic-derived monomers into L-DOPA under mild, aqueous conditions, overcoming key biochemical hurdles to achieve efficient production of the drug from plastic waste. Unlike conventional L-DOPA synthesis that relies on finite fossil fuels, involves harsh reaction conditions and generates significant waste, this biological upcycling approach offers a far more sustainable alternative for pharmaceutical production—though the technology currently remains in the proof-of-concept stage and awaits full industrial optimization.

The breakthrough addresses two pressing global challenges simultaneously: the growing plastic waste crisis and the unsustainability of fossil fuel-reliant chemical manufacturing. Each year, over 400 million metric tons of plastic are produced worldwide, with 360 million tons ending up as waste, most of which is landfilled or incinerated, causing carbon resource loss and heavy greenhouse gas emissions. Traditional plastic recycling is limited in value, while pharmaceutical production has long been tied to fossil resources, creating environmental burdens at every stage. For L-DOPA specifically, previous biological production attempts from glucose or amino acids suffered from low efficiency and poor industrial scalability, making this plastic-to-drug conversion a pivotal upgrade for sustainable drug manufacturing.

Beyond core drug production, the study also builds a preliminary carbon-neutral production cycle by integrating microalgae to capture carbon dioxide generated during the conversion process, and successfully validates the technology's applicability to real-world plastic waste—including post-consumer PET bottles and industrial plastic foils. This verifies the practicality of plastic waste upcycling in pharmaceutical production, and demonstrates the potential to turn low-value plastic waste into high-value medical resources, rather than just recycling it into low-grade plastic products.

The significance of this research extends far beyond a single drug production breakthrough: it forges an unprecedented link between plastic circular economy and the pharmaceutical industry, proving the feasibility of converting plastic waste into high-value pharmaceutical compounds. It not only provides a new sustainable solution for addressing global plastic pollution, but also offers a novel path for the pharmaceutical industry to decouple from fossil fuel reliance and reduce its environmental footprint. For the PET industry in particular, the technology unlocks a new high-value-added direction for plastic waste utilization, elevating PET recycling from closed-loop material reuse to cross-industry high-value upcycling.

While the proof-of-concept is highly promising, the technology still requires further optimization for large-scale industrial application. Key areas for improvement include refining the production process for greater efficiency, removing contaminants from plastic waste feedstocks, and advancing the integration of carbon capture systems. Even so, this study stands as a milestone in sustainable science, laying a solid foundation for future industrialization of plastic-to-medicine upcycling and inspiring more cross-disciplinary innovations for environmental and healthcare sustainability.

Source Reference: https://www.news-medical.net/news/20260317/Scientists-turn-plastic-waste-into-Parkinsone28099s-drug-levodopa-using-engineered-bacteria.aspx